C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart C—Abbreviated Applications

21 C.F.R. § 314.97 (2026)

Supplements and other changes to an approved ANDA

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 2008–2014 16citing cases
At a glance

Courts have cited this section in 16 opinions since 2008.

(a) General requirements. The applicant must comply with the requirements of §§ 314.70 and 314.71 regarding the submission of supplemental ANDAs and other changes to an approved ANDA.

(b) Different listed drug. An applicant may not supplement an ANDA to seek approval of a drug referring to a listed drug that is different from the current reference listed drug identified in the ANDA. This paragraph (b) applies if changes are proposed in a supplement to the ANDA such that the proposed product is a pharmaceutical equivalent to a different listed drug than the reference listed drug identified in the ANDA. A change of reference listed drug must be submitted in a new ANDA. However, notwithstanding the limitation described in this paragraph (b), an applicant may supplement the ANDA to seek approval of a different strength.

[81 FR 69653, Oct. 6, 2016]
The 16 cases that cite 21 C.F.R. § 314.97 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBartlett v. Mut. Pharm. Co., 659 F. Supp. 2d 279 (D.N.H. 2009).
cites § 314.97 4×cited by 21 cases
Where it cites § 314.97
“at 17987 (codified at 21 C.F.R. § 314.97 ). 5. Generic manufacturers’ reporting obligations The ANDA regulations promulgated after Hatch-Waxman require that “each applicant having an [ANDA] .”
The case’s holding
Federal drug-labeling law does not impliedly preempt state-law failure-to-warn claims against a generic drug manufacturer, because federal rules allow post-approval labeling changes that could have strengthened the warnings.
Later courts cite it for
“the fda's remarks in proposing and promulgating these regulations” · 2 citing courts
2
REDMensing v. Wyeth, Inc., 588 F.3d 603 (8th Cir. 2009).
cites § 314.97 2×cited by 56 cases
Reversed by the U.S. Supreme Court in this case: PLIVA, Inc. v. Mensing (2011).
Where it cites § 314.97
“Yet, 21 C.F.R. § 314.97 compels generic manufacturers to “comply with the requirements of § []314.”
The case’s holding
A brand name manufacturer owes no duty of care to warn of risks that are legally mandated by generic label requirements (stretching the concept of foreseeability too far).
Later courts cite it for
“intend to communicate with their customers, not the customers of their competitors.” · 3 citing courts
3
GREENDemahy v. Wyeth Inc., 586 F. Supp. 2d 642 (E.D. La. 2008).
cites § 314.97 5×cited by 8 cases
Where it cites § 314.97
“Finally, this excerpt from § N of the 1989 Proposed Rule sheds light on the meaning of 21 C.F.R. § 314.97 (discussed in further detail below in section C(3)).”
Later courts cite it for
“whether a generic drug that has already been approved via the anda process can change its label to include new or different warnings without fda approval.” · 2 citing courts
4
REDDemahy v. Actavis, Inc., 593 F.3d 428 (5th Cir. 2010).
cites § 314.97 2×cited by 37 cases
Reversed by the U.S. Supreme Court in this case: PLIVA, Inc. v. Mensing (2011).
Where it cites § 314.97
“On the other hand, what the FDA clearly did do to implement Hatch-Waxman cuts against Actavis’s position, or at the very least muddies congressional and agency intent: it promulgated 21 C.F.R. § 314.97 , entitled “Supplements and other changes to an approved abbreviated…”
The case’s holding
Federal regulatory requirements for generic drugs do not preempt state law failure-to-warn claims because manufacturers can comply with both sets of laws through available regulatory processes.
Later courts cite it for
“generic manufacturers cannot send 'dear doctor' letters without prior fda approval” · 2 citing courts
5
GREENDorsett v. Sandoz, Inc., 699 F. Supp. 2d 1142 (C.D. Cal. 2010).
cites § 314.97 3×cited by 15 cases
Where it cites § 314.97
“70 (concerning supplements and other changes to an approved application); 21 C.F.R. § 314.97 (applying §§ 314.70 and 314.”
6
GREENYanise Germain v. Teva Pharm., USA, Inc, 756 F.3d 917 (6th Cir. 2014).
cites § 314.97 1×cited by 99 cases
Where it cites § 314.97
“Under current regulations, brand-name and generic manufacturers have different labeling responsibilities, even though both are authorized to use the label supplement procedures.”
The case’s holding
A complaint fails to state a plausible claim when it relies on allegations based upon information and belief rather than specific factual support.
Later courts cite it for
“the mere fact that someone believes something to be true does not create a plausible inference that it is true.” · 10 citing courts
7
YELLOWGaeta v. Perrigo Pharm. Co., 630 F.3d 1225 (9th Cir. 2011).
cites § 314.97 2×cited by 15 cases
Vacated (GVR) by L. Perrigo Co. v. Gaeta (2011): the Supreme Court's order in this case remanded it for further consideration; read the decision on remand before relying on it.
Where it cites § 314.97
“70 is expressly made applicable to ANDA holders by operation of 21 C.F.R. § 314.97 , which is located in Subpart C of the Regulations (entitled, “Abbreviated Applications”) and provides that ANDA applicants “shall comply with the requirements of §§ 314.”
8
GREENMorris v. Wyeth, Inc., 642 F. Supp. 2d 677 (W.D. Ky. 2009).
cites § 314.97 2×cited by 6 cases
Where it cites § 314.97
“150 , and based on its understanding of 21 C.F.R. § 314.97 . The Demahy court reasoned that because the CBE regulation applies to ANDA holders, generic drug manufacturers have the ability to unilaterally change their labels to conform to heightened state warnings.”
9
GREENStacel v. Teva Pharm., USA, 620 F. Supp. 2d 899 (N.D. Ill. 2009).
cites § 314.97 1×cited by 16 cases
Where it cites § 314.97
“But 21 C.F.R. § 314.97 is not silent — it states that generic drug manufacturers are obligated to comply with the same CBE provisions as brand-listed manufacturers are.”
Later courts cite it for
“one of the benefits to manufacturers who opt for the anda procedure is that they are required only to conduct 'bioequivalency' studies that establish that the generic and the reference-listed drug are pharmaceutically equivalent ....” · 3 citing courts
10
GREENVITATOE v. Mylan Pharm., Inc., 696 F. Supp. 2d 599 (N.D. W. Va. 2010).
cites § 314.97 2×cited by 3 cases
Where it cites § 314.97
“The circuit court’s analysis noted that the contention of the generic drug manufacturers, that they were prohibited from using the CBE process to modify or alter drug labels without FDA approval, was in direct conflict with 21 C.F.R. § 314.97 , which requires them to “ ‘comply…”
11
GREENFulgenzi v. Wyeth, Inc., 686 F. Supp. 2d 715 (N.D. Ohio 2010).
cites § 314.97 1×cited by 7 cases
Where it cites § 314.97
“Because of this requirement, the generic drug manufacturers, like generic manufacturers in the present case, argued that they were prohibited from implementing a unilateral change without FDA approval.”
Later courts cite it for
“multiple state law tort claims, including several claims sounding in fraud” · 3 citing courts
12
GREENKellogg v. Wyeth, 612 F. Supp. 2d 437 (D. Vt. 2009).
cites § 314.97 1×cited by 6 cases
Where it cites § 314.97
“As this Court wrote in its earlier opinion, 21 C.F.R. § 314.97 requires an ANDA applicant to comply with the requirements of §§ 314.”
Later courts cite it for
“does not come close to a hint that an unofficial fda interpretation at odds with the plain language of a regulation will have preemptive effect.” · 2 citing courts
13
GREENKellogg v. Wyeth, 612 F. Supp. 2d 421 (D. Vt. 2008).
cites § 314.97 1×cited by 5 cases
Where it cites § 314.97
“That section provides that "labeling shall be revised to include a warning as soon as there is reasonable evidence of an association of a serious hazard with a drug; a causal relationship need not have been proved.”
14
NEUTRALWilson v. Pliva, Inc., 640 F. Supp. 2d 879 (W.D. Ky. 2009).
cites § 314.97 2×cited by 3 cases
Where it cites § 314.97
“150 , and based on its understanding of 21 C.F.R. § 314.97 . The Demahy court reasoned that because the CBE regulation applies to ANDA holders, generic drug manufacturers have the ability to unilaterally change their labels to conform to heightened state warnings.”
15
GREENBartlett v. Mut. Pharm., 2009 DNH 144 (D.N.H. 2009).
cites § 314.97 4×cited by 0 cases
Where it cites § 314.97
“at 17987 (codified at 21 C.F.R. § 314.97 ). 5. Generic manufacturers’ reporting obligations The ANDA regulations promulgated after Hatch-Waxman require that “each applicant having an [ANDA] .”
16
REDGladys Mensing v. Wyeth, Inc., No. 08-3850 (8th Cir. Nov. 27, 2009).
cites § 314.97 1×cited by 0 cases
Where it cites § 314.97
“21 C.F.R. §§ 314.97 , 201.57(e). As Judge William K.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200820112014

One bar per year. Tallest: 8 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
8th Cir.2W.D. Ky.2D.N.H.2D. Vt.25th Cir.16th Cir.19th Cir.1C.D. Cal.1

The 8 courts with the most citing cases, of 12 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com